🔗 Permalink

Inventor profile of:

Daniela Cocconi

City:

Parma

Country:

Italy

Published Applications:

20

Last publication date:

2025-02-13

Top Assignees for applications by Daniela Cocconi

The entities that hold a legal rights for patent applications filed by inventor Cocconi Daniela:

Chiesi Farmaceutici S.p.A. 19 Parma, Italy

Recent patent applications by Cocconi Daniela

Daniela Cocconi from Parma, IT has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-02-13

US20250050042A1

Human necessities

DRY POWDER FORMULATIONS FILLED IN AN INHALER WITH IMPROVED RESISTANCE TO HUMIDITY

#2 | 2023-11-16

US20230364015A1

Human necessities

PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES

#3 | 2019-07-18

US20190216731A1

Human necessities

PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES

#4 | 2018-10-18

US20180296573A1

Human necessities

Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

#5 | 2018-05-17

US20180133161A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#6 | 2016-12-08

US20160354314A1

Human necessities

PROCESS FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION

#7 | 2015-12-03

US20150342936A1

Human necessities

Dry powder formulation comprising a phosphodiesterase inhibitor

#8 | 2015-11-12

US20150320691A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#9 | 2015-07-23

US20150202159A1

Human necessities

Process for preparing carrier particles for dry powders for inhalation

#10 | 2015-06-18

US20150164915A1

Human necessities

Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

#11 | 2013-07-25

US20130189324A1

Human necessities

Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

#12 | 2012-04-05

US20120082727A1

Human necessities

USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

#13 | 2012-02-09

US20120031403A1

Human necessities

Dry powder formulation comprising a phosphodiesterase inhibitor

#14 | 2011-10-27

US20110262547A1

Human necessities

Process for preparing carrier particles for dry powders for inhalation

#15 | 2011-10-27

US20110262543A1

Human necessities

PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES

#16 | 2011-04-28

US20110097409A1

Human necessities

PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION

#17 | 2010-10-28

US20100269825A1

Human necessities

INHALATION PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO] ETHYL]-2(1H)-QUINOLINONE AND A CORTICOSTEROID

#18 | 2010-03-04

US20100055192A1

Human necessities

Micronized particles of low-dosage strength active agents for powder formulations for inhalation

#19 | 2009-07-30

US20090192187A1

Chemistry; metallurgy

DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG

#20 | 2007-08-30

US20070202053A1

Human necessities

Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient

InventorID:

353821 ⎘